These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23932726)

  • 1. Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone.
    Roberts RL; Wallace MC; Wright DF; Cadzow M; Dalbeth N; Jones PB; Stamp LK; Harrison AA; Black MA; Merriman TR
    Joint Bone Spine; 2014 Mar; 81(2):160-3. PubMed ID: 23932726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity.
    Hollis-Moffatt JE; Gow PJ; Harrison AA; Highton J; Jones PB; Stamp LK; Dalbeth N; Merriman TR
    Arthritis Res Ther; 2011 Jun; 13(3):R85. PubMed ID: 21658257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
    Lee MH; Graham GG; Williams KM; Day RO
    Drug Saf; 2008; 31(8):643-65. PubMed ID: 18636784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets.
    Phipps-Green AJ; Hollis-Moffatt JE; Dalbeth N; Merriman ME; Topless R; Gow PJ; Harrison AA; Highton J; Jones PB; Stamp LK; Merriman TR
    Hum Mol Genet; 2010 Dec; 19(24):4813-9. PubMed ID: 20858603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzbromarone in the treatment of gout.
    Azevedo VF; Kos IA; Vargas-Santos AB; da Rocha Castelar Pinheiro G; Dos Santos Paiva E
    Adv Rheumatol; 2019 Aug; 59(1):37. PubMed ID: 31391099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uricosuric medications for chronic gout.
    Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010457. PubMed ID: 25392987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control sample sets.
    Hollis-Moffatt JE; Xu X; Dalbeth N; Merriman ME; Topless R; Waddell C; Gow PJ; Harrison AA; Highton J; Jones PB; Stamp LK; Merriman TR
    Arthritis Rheum; 2009 Nov; 60(11):3485-92. PubMed ID: 19877038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
    Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human leukocyte antigen locus haplotype confers risk for allopurinol-related adverse effects in Caucasian patients with gout.
    Roberts RL; Wallace MC; Harrison A; Dalbeth N; Merriman TR; Stamp LK
    Pharmacogenet Genomics; 2015 Aug; 25(8):412-5. PubMed ID: 26049586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes.
    Uchida S; Shimada K; Misaka S; Imai H; Katoh Y; Inui N; Takeuchi K; Ishizaki T; Yamada S; Ohashi K; Namiki N; Watanabe H
    Drug Metab Pharmacokinet; 2010; 25(6):605-10. PubMed ID: 20962433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allopurinol for chronic gout.
    Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout.
    Wrigley R; Phipps-Green AJ; Topless RK; Major TJ; Cadzow M; Riches P; Tausche AK; Janssen M; Joosten LAB; Jansen TL; So A; Harré Hindmarsh J; Stamp LK; Dalbeth N; Merriman TR
    Arthritis Res Ther; 2020 Mar; 22(1):45. PubMed ID: 32164793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aotearoa New Zealand Māori and Pacific Population-amplified Gout Risk Variants:
    Ji A; Shaukat A; Takei R; Bixley M; Cadzow M; Topless RK; Major TJ; Phipps-Green A; Merriman ME; Hindmarsh JH; Stamp LK; Dalbeth N; Li C; Merriman TR
    J Rheumatol; 2021 Nov; 48(11):1736-1744. PubMed ID: 34210831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.